Up to 7,000 antibodies in parallel · 1 mg guaranteed per candidate · From 15 business days
Calculate your project price Discuss your project
Built for high-throughput screening
From focused panels to large screening campaigns, our HTP workflow combines high parallelization, sufficient material for early characterization, and rapid delivery to accelerate lead selection.
7,000
antibody candidates in parallel
Produce up to 7,000 antibody candidates in parallel for large-scale screening programs.
1 mg
guaranteed per candidate
Enough purified material for multi-criteria characterization before selecting candidates for scale-up.
15
business days
From gene synthesis to purified antibodies, helping you move from candidate panel to experimental testing faster.
Smarter lead selection
Selecting the right lead requires more than binding data. With a minimum of 1 mg purified antibody guaranteed per candidate, you have enough material to go beyond a single binding readout and start evaluating developability earlier.
Go beyond a single ELISA readout: test each candidate across a wider panel of assays, simultaneously.
Identify liabilities before they become problems. 1 mg is enough to run stability and aggregation tests from your very first screening round.
Get all the data you need in one pass, no intermediate scale-up required to complete your characterization.
Ready to screen your antibody candidates?Whether you need to produce a focused panel or several thousand candidates, our scientists can help define the most suitable production and characterization strategy.
Discuss your projectGet a project estimate
Why the guaranteed quantity matters
| ProteoGenix HTP service | Typical HTP offering* | |
|---|---|---|
| Purified quantity per candidate | 1 mg guaranteed per candidate | Typically 50 µg to a few hundred µg |
| Early characterization | Multi-criteria characterization possible | Typically focused on purity, concentration and an initial binding readout |
| Downstream testing | Multiple assays from the material received | Additional material may be required for broader testing |
| Lead selection | More data available before scale-up | Further production may be required for deeper characterization |
* Based on ProteoGenix competitive benchmarking of publicly available HTP antibody production services. Offer specifications may vary by provider and project.
Characterization
Keep candidate selection aligned with the properties that matter for your program rather than relying on a single screening readout.
Purity and structural integrity
Binding activity and functional validation
Early developability assessment
Identity and post-translational modifications
Use our price calculator to estimate the cost of your high-throughput antibody production project based on your antibody format, number of candidates, required quantity and optional characterization services.
ProteoGenix produces a broad range of antibody formats in CHO cells so you can screen the molecule that matches your application without changing CRO between formats.
Full length
IgG
Full-length recombinant antibodies for screening, binding and functional workflows.
Fragments
Fab
Fab production for programs requiring antigen-binding fragments.
Fragments
scFv
Single-chain variable fragments for compact recombinant antibody formats.
Single-domain
VHH
Single-domain antibody formats for discovery and screening workflows.
Complex formats
Bispecific antibodies
Specify your desired architecture; our team can discuss construct requirements before production.
Custom
Other formats
IgA, IgM, IgE, Fc-fusions and other custom formats can be discussed with the scientific team.
Delivery : Full report + purified samples shipped.
Your HTP candidates are expressed on XtenCHO™ Race, ProteoGenix’s in-house transient CHO platform, developed and validated for demanding antibody projects.
High-productivity CHO expression
Internal benchmarks show 1.5- to 9.7-fold improvements in yield, depending on the antibody, with yields up to 1.8 g/L.
Competitive cost as you scale: higher titers and reduced culture volumes support efficient HTP and larger production workflows.
Scientific evidence
Li Y, Wu J, Li J, et al. Monoclonal antibody against canine distemper virus H protein potently neutralizes the giant panda-derived strain. AMB Express. 2026;16:5. view publication
Bonduelle O, Colin L, Della Pia EA, et al. Dichotomy in Neutralizing Antibody Induction to Peptide-Conjugated Vaccine in Squalene Emulsion Contrast With Aluminum Hydroxide Formulation. Front Immunol. 2022;13:848571. view publication
Ball JA, et al. Susceptibility of broad reactivity nanobodies to resistance mutations in the S2 domain of SARS-CoV-2 predicted by yeast display deep mutational scanning. Front Immunol. 2026;16:1726449. view publication
Renn A, et al. Heterologous saRNA prime – multivalent protein boost strategy induces broad and durable immunity against SARS-CoV-2 and MERS-CoV. Sci Rep. 2026;16:14565.
Because ProteoGenix runs the same CHO system at every scale, your lead sequences progress directly from HTP to larger production. The antibody characterized during screening is the same molecule produced at scale.
mg → gram
Transient antibody production services
gram → kilogram
Stable cell line development service
Case reports
18 antibody variants rapidly expressed with >90% purity, streamlining candidate selection and accelerating development.
10.63mg recombinant antibodies delivered at >90% purity, meeting preclinical quality and yield standards.
